Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-GPRC5D CAR-T for relapsed/refractory multiple myeloma
ChiCTR2100048888Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jul 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CT071 in multiple myeloma (MM), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: overall response rate. Started Jul 2021; status: recruiting.
02
Drugs
CT071
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100048888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048888.